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Background: The high glucose-induced proliferation of vascular smooth muscle cells (VSMCs) plays an important role
in the development of diabetic vascular diseases. In a previous study, we confirmed that Interferon regulatory factor-1
(Irf-1) is a positive regulator of the high glucose-induced proliferation of VSMCs. However, the mechanisms remain to
be determined.
Methods: The levels of cyclin/CDK expression in two cell models involving Irf-1 knockdown and overexpression were
quantified to explore the relationship between Irf-1 and its downstream effectors under normal or high glucose
conditions. Subsequently, cells were treated with high glucose/NAC, normal glucose/H2O2, high glucose/U0126 or
normal glucose/H2O2/U0126 during an incubation period. Then proliferation, cyclin/CDK expression and cell cycle
distribution assays were performed to determine whether ROS/Erk1/2 signaling pathway was involved in the Irf-1-
induced regulation of VSMC growth under high glucose conditions.
Results: We found that Irf-1 overexpression led to down-regulation of cyclin D1/CDK4 and inhibited cell cycle
progression in VSMCs under normal glucose conditions. In high glucose conditions, Irf-1 overexpression led to an up-
regulation of cyclin E/CDK2 and an acceleration of cell cycle progression, whereas silencing of Irf-1 suppressed the
expression of both proteins and inhibited the cell cycle during the high glucose-induced proliferation of VSMCs.
Treatment of VSMCs with antioxidants prevented the Irf-1 overexpression-induced proliferation of VSMCs, the up-
regulation of cyclin E/CDK2 and the acceleration of cell cycle progression in high glucose conditions. In contrast, under
normal glucose conditions, H2O2 stimulation and Irf-1 overexpression induced cell proliferation, up-regulated cyclin E/
CDK2 expression and promoted cell cycle acceleration. In addition, overexpression of Irf-1 promoted the activation of
Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the
proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high
glucose or normal glucose/H2O2 conditions.
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Conclusions: These results demonstrate that the downstream effectors of Irf-1 are cyclin E/CDK2 during the high
glucose-induced proliferation of VSMCs, whereas they are cyclin D1/CDK4 in normal glucose conditions. The Irf-1
overexpression-induced proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle
progression are associated with ROS/Erk1/2 signaling pathway under high glucose conditions.
Keywords: Vascular smooth muscle cells, Cell proliferation, Interferon regulatory factor 1, Reactive oxygen species, Cell
cycleIntroduction
The high glucose-induced proliferation of vascular smooth
muscle cells (VSMCs) plays an important role in the devel-
opment of diabetic vascular diseases. However, the mo-
lecular mediators responsible for VSMC proliferation
remain to be determined. We have previously shown that
overexpression of Interferon regulatory factor-1 (Irf-1) ac-
celerates the proliferation of VSMCs and that down-
regulation of Irf-1 expression significantly depresses the
proliferation of VSMCs under high glucose conditions. Irf-
1 has also been shown to be a positive regulator of the high
glucose-induced proliferation of VSMCs. Interestingly, our
previous data demonstrated that Irf-1 overexpression has
an anti-proliferative effect under normal glucose condi-
tions, and it was suggested that the contradictory results
were caused by high glucose levels [1]. Irf-1, a transcrip-
tional regulator, most likely causes this discrepancy by
regulating downstream effector genes under high glucose
conditions that are different from the genes it regulates
under normal physiological conditions.
Originally, Irf-1 was known as a transcription factor
that recognizes regulatory elements in the promoters of
interferon-beta and some interferon-inducible genes.
Now by increasing evidence, the transcription factor has
been defined as having the effect of regulating prolifera-
tion of various cell types including tumor cells and som-
atic cells [2-4]. Several potential downstream mediators
of the growth-regulatory activity of Irf-1 have been
identified, which include p53, p21, cyclins and cyclin-
dependent kinase (CDK) [5-8]. Cyclins and CDK are
downstream effector genes that control cell cycle check-
points, suggesting that Irf-1 is involved in cell cycle
regulation. The involvement of Irf-1 in cell cycle regula-
tion may partly explain the effect of this gene in regulat-
ing VSMC growth.
Cell-cycle progression is regulated by cyclins and CDK.
In early G1, certain events can promote transcription of
cyclin D protein, which forms a cyclin D/CDK4 complex
that phosphorylates the retinoblastoma (Rb), resulting in
the gene expression and the formation of cyclin E/CDK2
complex. The cyclin E-CDK2 phosphorylates a broad var-
iety of proteins and promotes cell-cycle progression to late
G1, leading to the formation of the cyclin A/CDK2 com-
plex, which promotes cell-cycle progression through theG1/S phase into S phase. In the above-mentioned signal-
ing cascade, cyclin D/CDK4 and cyclin E/CDK2 are
known as two key points that promote the G1/S-phase
transition in cell cycle regulation [9]. However, the rela-
tionship between Irf-1 and the cyclins/CDK during the
high glucose-induced proliferation of VSMCs needs to be
confirmed. Furthermore, the glucose-dependent mechan-
ism by which Irf-1 acts as a positive or negative regulator
of VSMC growth needs to be elucidated.
In this study, two cell models involving Irf-1 knockdown
and overexpression were established as previously de-
scribed [1]. The levels of cyclin/CDK expression in two
cell models were quantified to explore the relationship be-
tween Irf-1 and its downstream effectors associated with
cell cycle regulation under normal or high glucose condi-
tions. Subsequently, cells were treated with high glucose/
N-acetyl-cysteine (NAC) and normal glucose/H2O2 or
high glucose/U0126 and normal glucose/H2O2/U0126
during an incubation period. And then proliferation, cyc-
lin/CDK expression and cell cycle distribution assays were
performed to determine whether reactive oxygen species
(ROS)/Erk1/2 signaling pathway was involved in the Irf-1-
induced regulation of VSMC growth under high glucose
conditions. In addition, the levels of phospho-Erk1/2 ex-
pression in two cell models involving Irf-1 knockdown
and overexpression were quantified to explore the rela-
tionship between Irf-1 and activation of Erk1/2 under high
glucose or ROS stimulation.
Methods
Cell culture and gene transfer
All experimental procedures were conducted in con-
formity with the institutional guidelines for the care and
use of laboratory animals of the Second Military Med-
ical University (Shanghai, China) and conformed to the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals. The methods employed for
VSMC culture and gene transfer were described previ-
ously [1]. Briefly, VSMCs were grown from explants of
the thoracic aorta from SD rats. Cells between passages
3 and 6 were used in the experiments. Complementary
oligonucleotide sequences were designed as small RNA
interfering sequences according to IRF-1 cDNA se-
quences. The sequences were analyzed via BLAST
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sequence homology to other genes. Small RNA interfer-
ing sequences (siIRF-1) were: sense, 5′ -GCC CAA
CUC UCU ACU GUC Utt-3′; antisense, 5′ -AGA CAG
UAG AGA GUU GGG Ctt-3′. The lentiviral vector
pGCsi-FU-Irf-1 was obtained by inserting the siIRF-1
into pGC-FU-GFP (GeneChem, Shanghai, China), and
the lentiviral vector pGC-FU-Irf-1 was obtained by
subcloning the full-length Irf-1 cDNA (GenBank acces-
sion No. NM_012591.1) into pGC-FU-GFP (Additional
file 1). The Irf-1 sequence was purchased commercially
from GeneChem.
The pGCsi-FU-Irf-1 or pGC-FU-Irf-1 plasmid to-
gether with pHelper 1.0 and pHelper 2.0 plasmids
(GeneChem) were cotransfected into 293 T cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) to pro-
duce lentiviral stocks. The blank vector pGC-FU-GFP
was utilized as a negative control. After the viral ti-
ters were determined, lentiviral particles were used to
infect VSMCs.
Intracellular ROS measurement
ROS levels were determined by measuring the oxidative
conversion of DCFH-DA to fluorescent compound dich-
lorofluorescin. VSMCs in 96-well plates were incubated
with normal glucose (5.5 mM) or high glucose (25 mM)
solution for 2, 4 and 6 days. Thereafter, the medium was
removed and replaced with serum-free medium. DCFH-
DA (Beyotime Institute of Biotechnology, Jiangsu, China)
stock solution (10 mM) was diluted 1000-fold in serum-
free medium, and was added to each well of 96-well
plates (10 uM). The cells were incubated for 25 min and
then DCF fluorescence was determined at 520 nm fol-
lowing excitation with 488 nm light from an argon laser
with a FACscan. The results were expressed as relative
fluorescence intensity per 104 cells.
Cell proliferation and cycle assay
Transfected VSMCs were seeded onto 6-well plates at a
density of 1 × 105 cells/well in 2 ml of DMEM containing
10% FBS with normal glucose (5.5 mM). After 24 h, G0/
early G1 synchronization was achieved through serum
deprivation (0% FBS). Subsequently, the medium was
switched to DMEM containing 10% FBS with normal
glucose/H2O2 (0.06 mmol/L), normal glucose/H2O2/
U0126 (10 uM), high glucose (25 mM)/NAC (20 mmol/
L) and high glucose/U0126, respectively. For the meas-
urement of cell proliferation under normal glucose and
high glucose conditions, after a 5-day incubation period,
cell growth and viability were analyzed via cell counting
and using the EdU assay. Additionally, flow cytometry
was employed to detect the cell cycle distribution of
transfected VSMCs in normal glucose/H2O2, normal glu-
cose/H2O2/U0126, high glucose/NAC and high glucose/U0126 conditions, respectively. The obtained data are
expressed as the mean ± SD. Differences were assessed
using Dunnett’s test, and a value of P < 0.05 was consid-
ered statistically significant.
Western blot analysis of cyclins and CDK
Transfected VSMCs, including cells transfected with
pGCsi-FU-Irf-1, pGCFU-Irf-1 or the pGC-FU vector, were
incubated under normal glucose (5.5 mM), normal glu-
cose/H2O2 (0.06 mmol/L), normal glucose/H2O2/U0126
(10 uM), high glucose (25 mM), high glucose/NAC
(20 mmol/L) and high glucose/U0126 conditions, respect-
ively. After 5 days, the cells were collected and lysed in
RIPA lysis buffer (Beyotime). Next, the extracted proteins
were resolved via SDS–PAGE and electroblotted onto
PVDF membranes (Beyotime). The proteins of interest
were detected with anti-cyclin D1, anti-cyclin E, anti-
CDK2 or anti-CDK4 using the ECL (Beyotime) chemilu-
minescence detection system. Band intensities were
analyzed using Multi-Analyst software. β-actin levels
were used to normalize the signal intensity. The inten-
sity data were then subjected to statistical analysis, and
the differences were assessed via Dunnett’s test. A value
of P < 0.05 was considered statistically significant.
Immunofluorescence staining
Transfected VSMCs, including cells transfected with
pGCsi-FU-Irf-1, pGCFU-Irf-1 or the pGC-FU vector,
were incubated under normal glucose (5.5 mM), normal
glucose/H2O2 (0.06 mmol/L), high glucose (25 mM),
high glucose/NAC (20 mmol/L) conditions, respect-
ively. After 5 days, the cells were plated at 50% conflu-
ence in 12-well plates, rinsed twice with PBS, and fixed
in 95% ethanol for 30 min at room temperature. Rabbit
anti phospho-Erk1/2 (Cell Signaling Technology, Inc.)
was applied to incubate the cells at 4°C overnight. After
incubation of the cells with secondary antibodies of
anti- rabbit IgG-TRITC (Sigma–Aldrich, Inc.) used at a
1:100 dilution for 60 min at room temperature, fluores-
cence imaging was visualized with an Olympus IX70
microscope. The percentage of positive cells was deter-
mined by counting positive staining cells and total cells
in one visual field under a microscope. At least three
fields (around 300 cells) were counted in each sample.
Average data are presented as means ± SD and com-
pared with Dunnett-test.
Results
Irf-1 overexpression decreases the proliferation activity,
inhibits cell cycle progression, and down-regulates cyclin
D1/CDK4 expression in VSMCs under normal glucose
conditions
We have reported previously that Irf-1 overexpression
significantly depresses the proliferation of VSMCs under
Zhang et al. Cardiovascular Diabetology 2013, 12:147 Page 4 of 13
http://www.cardiab.com/content/12/1/147normal glucose conditions [1]. The finding is consistent
with the results obtained in this study, which showed
that under normal glucose conditions, more than 88% of
VSMCs transfected with pGC-FU-Irf-1 were in the G0/
G1 phase of the cell cycle, and the percentage of cells in
S and G2/M phases was significantly lower compared to
untransfected cells (Table 1). These results indicate that
Irf-1 overexpression decreased the proliferation activity
and inhibited cell cycle progression in VSMCs.
To determine the effect of Irf-1 overexpression on
cyclins and CDK under normal glucose conditions, VSMCs
were transfected with pGCFU-Irf-1, and the expression of
cyclin D1, cyclin E, CDK2 and CDK4 was examined via
Western blot analysis. The results showed that the ex-
pression of cyclin D1 and CDK4 in VSMCs transfected
with pGC-FU-Irf-1 was significantly lower than the
levels in untransfected VSMCs or VSMCs transfected
with the blank pGC vector (pGC-FU) (P < 0.01, n = 5;
Figure 1), indicating that Irf-1 overexpression down-
regulated cyclin D1 and CDK4 expression under normal
glucose conditions. In contrast, no significant difference
was observed in the expression of cyclin E or CDK2
between VSMCs transfected with pGC-FU-Irf-1 and
control cells under normal glucose conditions (P > 0.05,






G0/G1 64.8 ± 2.7 65.0
S 21.2 ± 1.2 20.9
G2/M 13.9 ± 1.3 14.1
High glucose/NAC
G0/G1 69.5 ± 2.7 69.9
S 18.7 ± 1.6 19.1
G2/M 11.7 ± 1.5 11.1
Normal glucose
G0/G1 80.8 ± 3.3 80.3
S 11.8 ± 1.2 12.2
G2/M 7.3 ± 1.1 7.5 ±
Normal glucose/H2O2
G0/G1 72.0 ± 2.9^ 73.4 ±
S 17.1 ± 2.2^ 16.8 ±
G2/M 10.8 ± 1.3^ 9.9 ±
High glucose/U0126
G0/G1 71.3 ± 2.8# 72.5 ±
S 17.9 ± 1.6# 17.4 ±
G2/M 10.9 ± 1.7# 10.2 ±
Normal glucose/H2O2/U0126
G0/G1 70.3 ± 2.1^ 68.9 ±
S 17.5 ± 1.8^ 18.5 ±
G2/M 12.1 ± 1.7^ 12.5 ±
Values are mean ± SD from triplicate determinations repeated in 4 separate experim
*P < 0.05 vs. corresponding values in untransfected VSMCs; ^P < 0.05 vs. correspond
in VSMCs under high glucose.Manipulation of Irf-1 levels affects the proliferation
activity, the cell cycle progression, the expression of
cyclin E/CDK2 in VSMCs in the presence of high glucose
It has been shown in the previous study that overexpression
of Irf-1 accelerates the proliferation of VSMCs and that
down-regulation of Irf-1 expression significantly depresses
the proliferation of VSMCs under high glucose conditions
[1]. In this study, the results showed that under high
glucose conditions, VSMCs transfected with pGC-FU-
Irf-1 displayed a significantly greater percentage of cells
in S and G2/M phases, while cells transfected with
pGCsi-FU-Irf-1 exhibited a lower percentage of cells in
these phases compared to untransfected cells (Table 1).
This means that overexpression of Irf-1 promoted cell
cycle progression and silencing of Irf-1 caused the op-
posite effect under high glucose conditions.
To determine the effect of Irf-1 levels on cyclins and
CDK under high glucose conditions, VSMCs were trans-
fected with pGCsi-FU-Irf-1 and pGCFU-Irf-1, and the ex-
pression of cyclin D1, cyclin E, CDK2 and CDK4 was
determined through Western blot assays. The results
showed that the expression of cyclin E and CDK2 in
VSMCs transfected with pGCsi-FU-Irf-1 was significantly
lower than the expression recorded in untransfected







± 2.9 82.5 ± 3.2* 51.0 ± 2.4*
± 1.4 10.5 ± 1.1* 29.8 ± 1.6*
± 1.7 6.9 ± 0.9* 19.3 ± 1.7*
± 3.0 69.4 ± 1.3# 71.1 ± 3.4#
± 1.2 18.3 ± 1.5# 17.9 ± 2.1#
± 1.4 12.3 ± 1.3# 10.9 ± 2.1#
± 2.9 81.5 ± 3.7 88.4 ± 3.5*
± 1.3 11.3 ± 1.0 7.3 ± 1.1*
1.0 7.3 ± 1.2 4.2 ± 0.7*
3.1^ 82.5 ± 3.2* 55.5 ± 2.3*^
1.7^ 11.3 ± 1.2* 27.9 ± 2.3*^
1.7^ 6.1 ± 1.0* 16.7 ± 1.9*^
3.1# 70.6 ± 1.9# 69.8 ± 3.6#
2.0# 16.5 ± 1.6# 18.1 ± 1.9#
1.5# 12.8 ± 2.8# 12.0 ± 2.6#
3.6^ 69.8 ± 2.3^ 70.9 ± 3.2^
1.6^ 18.4 ± 1.7^ 17.8 ± 2.1^
1.5^ 11.9 ± 1.4^ 11.4 ± 1.9^
ents.
ing values in VSMCs under normal glucose; #P < 0.05 vs. corresponding values
Figure 1 Examination of the expression of cyclins/CDK in transfected VSMCs under normal glucose. a: Western blot analysis of cyclin D1,
CDK4, cyclin E and CDK2 after 5 days of incubation of the transfected VSMCs with normal glucose; b: quantitative assessment of cyclin/CDK
protein levels through integrated optical density analyses. *P <0.05; **P <0.01 versus corresponding values in untransfected VSMCs.
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silencing of Irf-1 suppressed the expression of the two
proteins under high glucose conditions. In contrast,
the expression of cyclin E and CDK2 in VSMCs trans-
fected with pGCFU-Irf-1 was significantly higher than
the levels in untransfected VSMCs and VSMCs trans-
fected with the blank pGC vector (P < 0.01, n = 5;
Figure 2), indicating that Irf-1 overexpression up-
regulated cyclin E and CDK2 under high glucose condi-
tions. In addition, no significant difference was observed
in the expression of cyclin D1 and CDK4 between VSMCs
transfected with pGCsi-FU-Irf-1 or pGC-FU-Irf-1 and
control cells under high glucose conditions (P > 0.05,
n = 5; Figure 2).Relationship between ROS and Irf-1-mediated
hyperglycemia-dependent VSMC proliferation
ROS production in VSMCs was measured by flow cy-
tometric analysis. The results showed that the level of
intracellular ROS under high glucose conditions was
higher than that under normal glucose conditions (P <
0.01, n = 12; Figure 3 and Table 2), which indicates that
high glucose treatment increased significantly the level
of intracellular ROS in VSMCs.
When VSMCs were treated with NAC, no significant dif-
ference in cell numbers or proliferation activity was ob-
served between VSMCs transfected with pGC-FU-Irf-1 and
control cells under high glucose conditions (P > 0.05, n =
12; Figure 4). In contrast, following the addition of H2O2 to
Figure 2 Examination of the expression of cyclins/CDK in transfected VSMCs under high glucose. a: Western blot analysis of cyclin D1,
CDK4, cyclin E and CDK2 after 5 days of incubation of the transfected VSMCs with high glucose; b: quantitative assessment of cyclin/CDK protein
levels through integrated optical density analyses. *P <0.05; **P <0.01 versus corresponding values in untransfected VSMCs.
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was significantly greater compared to untransfected VSMCs
and VSMCs transfected with the blank pGC vector under
normal glucose conditions (P < 0.01, n = 12; Figure 4).
These findings are consistent with the results obtained
using the EdU assay, which indicates that the proliferation
activity of VSMCs transfected with pGC-FU-Irf-1 was in-
creased significantly compared to untransfected VSMCs
and VSMCs transfected with the blank pGC vector in the
presence of H2O2 or ROS (P < 0.01, n = 12; Figure 4).
ROS affects Irf-1-dependent cyclin E/CDK2 expression and
cell cycle regulation under high glucose conditions
When VSMCs were treated with NAC, a potent antioxi-
dant, no significant difference in the expression of cyclinE or CDK2 was observed between VSMCs transfected
with pGC-FU-Irf-1 and control cells under high glucose
conditions, indicating that NAC blocked the Irf-1-induced
up-regulation of cyclin E and CDK2 under high glucose
conditions (P > 0.05, n = 5; Figire 5). After the addition of
H2O2 to the cells, the expression of the two proteins
in VSMCs transfected with pGC-FU-Irf-1 was significantly
higher than the expression levels observed in untransfected
VSMCs and VSMCs transfected with the blank pGC
vector under normal glucose conditions (P < 0.01, n = 5;
Figure 5), indicating that the Irf-1-mediated up-regulation
of cyclin E and CDK2 under high glucose conditions was
regulated by ROS.
To determine the effect of Irf-1 levels and ROS on
cell cycle regulation, the cell cycle distribution of
Figure 3 The intracellular ROS production was measured by flow cytometry analysis under high glucose or normal glucose conditions.
Values are showed as relative fold of fluorescence intensity measurement (High glucose/2 days =100). *P <0.05; **P <0.01 versus corresponding
values in VSMCs under normal glucose conditions. 2 days, 4 days and 6 days = VSMCs incubated with high glucose or normal glucose for 2 days,
4 days and 6 days.
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glucose conditions, VSMCs transfected with pGC-FU-
Irf-1 displayed a significantly greater percentage of cells
in S and G2/M phases, while cells transfected with
pGCsi-FU-Irf-1 exhibited a lower percentage of cells in
these phases compared to untransfected cells. In con-
trast, transfected VSMCs treated with NAC/high glu-
cose showed no significant difference in the percentage
of S and G2/M phases compared to the control cells
(Table 1). Under normal glucose conditions, more than
88% of VSMCs transfected with pGC-FU-Irf-1 were in
the G0/G1 phase of the cell cycle, and the percentage of
cells in S and G2/M phases was significantly lower
compared to untransfected cells. In contrast, VSMCs
transfected with pGC-FU-Irf-1 and treated with H2O2/
normal glucose showed a significantly greater percent-
age of cells in S and G2/M phases, while a lower per-








High glucose 100.0 ± 5.7** 122.3 ± 5.1** 116.5 ± 4.2**
Normal glucose 21.2 ± 2.0 24.3 ± 2.3 22.4 ± 2.1
Values are mean ± SD from triplicate determinations repeated in 4 separate
experiments. They are showed as relative fold of fluorescence intensity
measurement (High glucose/2 days =100).
2 days, 4 days and 6 days = VSMCs incubated with high glucose or normal
glucose for 2 days, 4 days and 6 days.
*P <0.05; **P <0.01 versus corresponding values in VSMCs under normal
glucose conditions.in these phases compared to untransfected cells (Table 1).
These results indicate that the Irf-1-mediated cell cycle ac-
celeration or arrest under high glucose conditions was
regulated by ROS.
Blocking Erk1/2 pathway affects Irf-1-dependent VSMC
proliferation, cyclin E/CDK2 expression, and cell cycle
regulation under high glucose conditions
When VSMCs were treated with U0126, the specific
Erk1/2 upstream kinase MEK inhibitor, no significant
difference in cell proliferation activity, cyclin E/CDK2
expression, and cell cycle distribution was observed
between VSMCs transfected with pGC-FU-Irf-1 and
control cells under high glucose conditions. Similarly,
there was no significant difference in the proliferation
activity, cyclin E/CDK2 expression, and the cycle dis-
tribution between pGC-FU-Irf-1-transfected VSMCs
and control cells with U0126 treatment under normal
glucose/H2O2 conditions (P > 0.05, n = 12; Figure 4)
(P > 0.05, n = 5; Figure 6) (Table 1). These findings
indicate that blocking Erk1/2 pathway inhibited Irf-
1-mediated ROS or hyperglycemia-dependent VSMC
proliferation.
Irf-1 regulates the activation of Erk1/2 in VSMC under
high glucose or normal glucose/H2O2 conditions
The phosphorylation of ERK1/2 (phospho-Erk1/2) was
determined by immunofluorescence staining. The percent-
age of phospho-Erk1/2 positive cells was low about 2-3%
under normal glucose or high glucose/NAC conditions,
while the percentage was great about 26-27% under high
Figure 4 Comparison of cell proliferation in transfected VSMCs following treatment with NAC, H2O2 or U0126. a: cell numbers were
counted with a hemocytometer; b: cell proliferation was also measured using the EdU assay; the presented data are the mean ± SD of triplicate
determinations repeated in four separate experiments. High glucose/NAC = cells incubated with high glucose and NAC for 5 days; normal
glucose/H2O2 = cells incubated with normal glucose and H2O2 for 5 days; High glucose/U0126 = cells incubated with high glucose and U0126 for
5 days; normal glucose/H2O2/U0126 = cells incubated with normal glucose, H2O2 and U0126 for 5 days. *P <0.05; **P <0.01 versus corresponding
values in untransfected VSMCs.
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VSMCs transfected with pGC-FU-Irf-1 displayed a signifi-
cantly greater percentage of phospho-Erk1/2 positive cells,
while cells transfected with pGCsi-FU-Irf-1 exhibited a
lower percentage of phospho-Erk1/2 positive cells com-
pared to untransfected cells under high glucose or nor-
mal glucose/H2O2 conditions. In contrast, transfected
VSMCs treated with high glucose/NAC or normal glu-
cose showed no significant difference in the percentageof phospho-Erk1/2 positive cells compared to the con-
trol cells (Figure 7) (Table 3). These results indicate that
overexpression of Irf-1 promoted the activation of Erk1/
2 and silencing of Irf-1 caused the opposite effect under
high glucose or normal glucose/H2O2 conditions.
Discussion
Hyperglycemia is a risk factor of cardiovascular morbid-
ity and mortality in patients [10]. It has a very important
Figure 5 Western blot analysis of cyclin E and CDK2 in transfected VSMCs following treatment with NAC or H2O2. a: Western blot
analysis of the expression of cyclin E and CDK2 protein levels in transfected VSMCs; b: quantitative assessment of cyclin E and CDK2 protein levels
through integrated optical density analyses. High glucose/NAC = cells incubated with high glucose and NAC for 5 days; normal glucose/H2O2 =
cells incubated with normal glucose and H2O2 for 5 days. *P <0.05; **P <0.01 versus corresponding values in untransfected VSMCs.
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dependent mechanisms responsible for cardiovascular
diseases. In particular, molecular mediators responding
for the High glucose-Induced diseases may prove to be a
potential target gene for disease treatment [11,12]. At
present, most of them remain to be determined. Irf-1, a
molecular mediator for vascular diseases, was previously
known as negative. However, several of recent studies
have provided evidences that Irf-1 was not a negative
mediator, but even a positive one [1,13,14].
Irf-1 displays tumor suppressor activity and is regarded
as a negative regulator of cell growth through regulating
downstream effector genes [3,15,16]. It is well known
that cyclin D and CDK4 form a complex that promotes
the G1/S-phase transition in cell cycle regulation. Kröger
et al. [6] reported that Irf-1 inhibits cell growth bysuppressing cyclin D/CDK4 gene transcription. Therefore,
cyclin D/CDK4 may be the downstream effector genes in-
volved in Irf-1-induced VSMC growth inhibition. In a pre-
vious study [1], we determined that Irf-1 overexpression
in VSMCs has an anti-proliferative effect under normal
glucose conditions, consistent with the tumor suppressor
activity of Irf-1. In this study, we confirmed that Irf-1
overexpression leads to the down-regulation of cyclin D1/
CDK4 and inhibits VSMC cell cycle progression under
normal glucose conditions, suggesting that cyclin D1/
CDK4 are downstream effector genes of Irf-1 with an
antiproliferative effect on VSMCs.
In contrast to the antiproliferative effect of Irf-1/normal
glucose on cells, we previously showed that Irf-1/high
glucose has a pro-proliferative effect on VSMCs [1]. The
likely mechanism underlying this discrepancy is that Irf-
Figure 6 Western blot analysis of cyclin E and CDK2 in transfected VSMCs following treatment with U0126. a: Western blot analysis of
the expression of cyclin E and CDK2 protein levels in transfected VSMCs; b: quantitative assessment of cyclin E and CDK2 protein levels through
integrated optical density analyses. High glucose/U0126 = cells incubated with high glucose and U0126 for 5 days; normal glucose/H2O2/U0126 = cells
incubated with normal glucose, H2O2 and U0126 for 5 days. *P <0.05; **P <0.01 versus corresponding values in untransfected VSMCs.
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fector genes under high glucose conditions that are
different from the genes it regulates under normal glu-
cose conditions. Cyclin E and its catalytic partner,
CDK2, are known to play important roles in the G1/S
checkpoint of the cell cycle [17]. In this study, we found
that Irf-1 overexpression up-regulated cyclin E/CDK2
expression and accelerated cell cycle progression. In
contrast, silencing of Irf-1 suppressed the expression of
these two proteins and inhibited the cell cycle during
the high glucose-induced proliferation of VSMCs. This
finding suggests that the downstream effector genes of
Irf-1 are cyclin E/CDK2 and that they are positively reg-
ulated under high glucose conditions, while cyclin D1/CDK4 are negatively regulated under normal glucose
conditions. In the cyclins/CDK signaling cascade, cyclin
D/CDK4 and cyclin E/CDK2 are known as sequential
activation that promotes the G1/S-phase transition.
Consequently, through downstream effectors cyclin D/
CDK4, Irf-1 could exert an anti-proliferative effect
under normal glucose conditions, but through cyclin E/
CDK2 it could accelerate proliferation under high glu-
cose conditions.
Irf-1 is regarded as a negative regulator of cell growth
under typical-state/normal glucose conditions. Why does
Irf-1 up-regulate cyclin E/CDK2 and promote the pro-
liferation of VSMCs under high glucose conditions?
Several studies have attributed this difference to ROS,
Figure 7 Representative negative or positive staining of phospho-Erk1/2 in VSMCs. High glucose = cells incubated with high glucose for
5 days; normal glucose = cells incubated with normal glucose for 5 days; High glucose/NAC = cells incubated with high glucose and NAC for
5 days; normal glucose/H2O2 = cells incubated with normal glucose and H2O2 for 5 days. Positive staining of phospho-Erk1/2 shows red and
transfected VSMCs display green (GFP).
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tion and promote cell cycle progression by activating
cyclins/CDK, as ROS levels increase steadily during the
high glucose-induced proliferation of VSMCs [18-21].
Accordingly, the possibility has been raised that ROS
are involved in the Irf-1/high glucose-induced prolifera-
tion of VSMCs. In the present study, we found that high
glucose treatment increased significantly the level of intra-





Normal glucose + 2.56 ± 0.33 2.92 ± 0.
++ 0.32 ± 0.03 0.39 ± 0.
Normal glucose + H2O2 + 19.7 ± 2.8^ 20.5 ± 2.
++ 6.1 ± 0.7^ 6.3 ± 0.6
High glucose + 21.8 ± 1.9 23.7 ± 2
++ 5.7 ± 0.8 6.2 ± 0.
High glucose + NAC + 3.04 ± 0.29# 3.17 ± 0.4
++ 0.51 ± 0.04# 0.31 ± 0.0
Values are mean ± SD from the determinations repeated in 4 separate experiments
by counting positive staining cells and total cells in three visual fields (around 3 × 3
*p < 0.05 vs. corresponding values in untransfected VSMCs; ^P < 0.05 vs. correspond
in VSMCs under high glucose.
+ represents positive; ++ represents strong positive.Irf-1 under high glucose conditions were treated with an-
tioxidants, a proliferation of VSMCs, an up-regulation of
cyclin E/CDK2 and an acceleration of cell cycle progres-
sion was not observed. In contrast, H2O2 stimulation
under normal glucose conditions in Irf-1-overexpressing
cells caused cell proliferation, an up-regulation of cyclin
E/CDK2 and cell cycle acceleration, suggesting that under
ROS or H2O2 stimulation, the positive regulatory activity






28 3.11 ± 0.34 2.65 ± .026
04 0.45 ± 0.02 0.24 ± 0.06
6^ 2.89 ± 0.59* 33.7 ± 2.9*^
^ 0.43 ± 0.05* 34.7 ± 2.8*^
.2 3.27 ± 0.28* 34.5 ± 3.8*
5 0.36 ± 0.03* 35.1 ± 3.2*
2# 3.13 ± 0.48 2.75 ± .034#
6# 0.48 ± 0.04 0.44 ± 0.05#
(12 samples). For one sample, the percentage of positive cells was determined
00 cells).
ing values in VSMCs under normal glucose; #P < 0.05 vs. corresponding values
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VSMC growth. ROS has been shown, via Erk1/2 pathway,
to mediate the cell proliferative effects [9,18]. In this study,
we observed that when VSMCs overexpressing Irf-1 were
treated with U0126, the specific Erk1/2 inhibitor abolished
the proliferation of VSMCs, the up-regulation of cyclin E/
CDK2 and the acceleration of cell cycle progression under
high glucose or normal glucose/H2O2 conditions. These
results indicate that Erk1/2 activation is required for Irf-1-
mediated hyperglycemia-dependent VSMC proliferation.
Taken together, above findings suggest the pathway of
Irf-1-mediated hyperglycemia-dependent VSMC prolifera-
tion. First, high glucose stimulation increases the level of
intracellular ROS in VSMCs. Subsequently, via Erk1/2
pathway, the increased ROS induces the up-regulation of
cyclin E/CDK2 which leads to the proliferation of VSMCs
and the acceleration of cell cycle. Because overexpression
of Irf-1 promotes the activation of Erk1/2 under high
glucose conditions, the positive regulatory activity of Irf-1
could play a role in hyperglycemia-dependent VSMC
proliferation.
In conclusion, we demonstrated that the downstream
effector genes of Irf-1 are cyclin E/CDK2 during the
high glucose-induced proliferation of VSMCs, whereas
they are cyclin D1/CDK4 under normal glucose condi-
tions. Irf-1 overexpression-induced VSMC proliferation,
an up-regulation of cyclin E/CDK2 and an acceleration
of cell cycle progression are associated with ROS/ERK1/
2 signaling pathway under high glucose conditions. The
findings of the present study may prove significant in
furthering our understanding of the development and
regulatory mechanisms of diabetic vascular diseases.
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